CAS: 1878-84-8; 4-Hydroxyphenoxyacetic Acid

上下游产品

CAS号70067-75-3 2-(4-羟基苯氧基)乙酸甲酯 | CAS号79-11-8 氯乙酸 | CAS号123-31-9 对苯二酚 | CAS号1877-75-4 对甲氧基苯氧乙酸 | CAS号38559-92-1 4-苯甲氧基苯氧基乙酸 | CAS号615-93-0 2,5-二氯-1,4-苯醌 | CAS号497-76-7 熊果苷 | CAS号20872-28-0 乙基2-(4-羟基苯氧基)乙酯 | CAS号37067-27-9 对苯二酚一硫酸钾 | CAS号108-95-2 苯酚 | CAS号22446-14-6 2-(4-hydroxyphe... | CAS号70067-75-3 2-(4-羟基苯氧基)乙酸甲酯 | CAS号13012-94-7 3,5-二溴-4-羟基苯氧基乙酸 | CAS号2245-53-6 氢醌-O,O'-二乙酸 | CAS号13427-53-7 4-(2-hydroxyeth... | CAS号20872-28-0 乙基2-(4-羟基苯氧基)乙酯 | CAS号98420-50-9 4-(2-aminoethox... | CAS号4385-47-1 1,4-dioxaspiro[...

📜对甲氧基苯氧乙酸置于盐酸体系中,化学反应生成4-羟基苯氧乙酸
参考文献:P-Hydroxyphenoxy Aliphatic Acids
标题:P-Hydroxyphenoxy Aliphatic Acids
摘要:
Doi:10.1021/ja01135A028

专利信息

专利号:US-2009099267-A1
优先权日:2005-05-27
标题 :Polymers, compositions and methods of making the same
发明人：KUMAR RAJESH; KUMAR JAYANT; PARMAR VIRINDER SINGH; WATTERSON ARTHUR C
权利人:UNIV MASSACHUSETTS
摘要:Polymers having a main chain having both aromatic units and aliphatic units (with repeating heteroatoms) and a side chain macromonomer are described. Methods of making these polymers using enzymatic synthesis and the applications of these polymers are also described.

专利号:US-6020341-A
优先权日:1994-12-01
标题 :Enediyne quinone imines and methods of preparation and use thereof
发明人：DANISHEFSKY SAMUEL J; SHAIR MATTHEW D; YOON TAEYOUNG; CHOU TING-CHAO; MOSNY KAROLINE K
权利人:SLOAN KETTERING INST CANCER
摘要:A quinone imine enediyne possessing cytotoxic activity towards cancer cells having general structure (I) wherein R 1 , R 2 and R 3 are independently the same or different and are H, Br, Cl, F, NH 2 , CO 2 H, OH, linear or branched alkyl, etc.; wherein R 4 is H, OH or linear or branched alkoxy, linear or branched alkoxycarbonyl, etc.; wherein R 5 is H, Br, Cl, F, Oâ•?, OH or S--SR, or linear or branched alkyl, etc.; wherein R 6 is H, Br, Cl, F, CO 2 H, OH or S--SR', or linear or branched alkyl, etc.; wherein R 7 is H, OH or S--SR', or linear or branched alkyl, linear or branched alkoxycarbonyl, linear or branched alkoxy or linear or branched hydroxyalkyl; and wherein R, R' and R' are independently the same or different and are linear or branched alkyl, linear or branched acyl or linear or branched alkoxyalkyl. Also provided are conjugates of the compound with cleavable peptides, enzymes, carbohydrates and monoclonal antibodies immunoreactive with cancer cells, as well as compositions comprising the analogues and conjugates, and methods of synthesis and treatment of tumos.

专利号:EP-1957644-B1
优先权日:2005-12-01
标 题 :Enzymatic encoding methods for efficient synthesis of large libraries

专利号:EA-002100-B1
优先权日:1996-12-23
标题:CYCLOALCYL COMPOUNDS, LACTAMS, LACTONES AND RELATED COMPOUNDS CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF INHIBITING THE SURVIVAL AND / OR SYNTHESIS OF β-AMYLOUS PEPTIDE SOFTWARE AGREED SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE, SOFTWARE AND SOFTWORK

专利号:US-5753458-A
优先权日:1994-06-10
标 题:Acylation method for penicillins and cephalosporins
发明人：CLAUSEN KIM; NIELSEN ANNETTE; PETERSEN NIELS; NIKOLOV ALEXANDER
权利人:GIST BROCADES BV
摘要:PCT No. PCT/EP95/02277 Sec. 371 Date Jan. 7, 1996 Sec. 102(e) Date Jan. 7, 1996 PCT Filed Jun. 12, 1995 PCT Pub. No. WO95/34675 PCT Pub. Date Dec. 21, 1995A method for providing a semisynthetic beta -lactam antibiotic by enzyme catalyzed acylation of the parent beta -lactam with an activated derivative of the side chain acid wherein a modulator, which consists of one or more compounds different from the reactants and the reaction product and which suppresses the hydrolysis of the activated derivative of the side chain acid and the desired product more than it suppresses the synthesis of the desired product, is added to the reaction mixture, at the beginning of the reaction process, in a concentration from about 0.2 to 100x103 mu m.\\!

专利号:US-9878999-B2
优先权日:2011-03-24
标题 :Proteasome chymotrypsin-like inhibition using PI-1833 analogs
发明人：LAWRENCE HARSHANI R; SEBTI SAID M; OZCAN SEVIL
权利人:H LEE MOFFITT CANCER CT & RES
摘要:Focused library synthesis and medicinal chemistry on an oxadiazole-isopropylamide core proteasome inhibitor provided the lead compound that strongly inhibits CT-L activity. Structure activity relationship studies indicate the amide moiety and two phenyl rings are sensitive toward synthetic modifications. Only para-substitution in the A-ring was important to maintain potent CT-L inhibitory activity. Hydrophobic residues in the A-ring's para-position and meta-pyridyl group at the B-ring significantly improved inhibition. The meta-pyridyl moiety improved cell permeability. The length of the aliphatic chain at the para position of the A-ring is critical with propyl yielding the most potent inhibitor, whereas shorter (i.e. ethyl, methyl or hydrogen) or longer (i.e. butyl, propyl and hexyl) chains demonstrating progressively less potency. Introduction of a stereogenic center next to the ether moiety (i.e. substitution of one of the hydrogens by methyl) demonstrated chiral discrimination in proteasome CT-L activity inhibition (the S-enantiomer was 35-40 fold more potent than the R-enantiomer).